H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Arvinas Holding Company (ARVN) today and set a price target of $60.00. The company’s shares closed last Tuesday at $53.14, close to its 52-week high of $57.13.
According to TipRanks.com, Fein is a 5-star analyst with an average return of 7.7% and a 46.1% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Constellation Pharmaceuticals, and Proteostasis Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arvinas Holding Company with a $63.75 average price target, representing a 13.0% upside. In a report issued on April 14, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $75.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $57.13 and a one-year low of $15.19. Currently, Arvinas Holding Company has an average volume of 351.1K.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ARVN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.
